IL15 and head and neck squamous cell carcinoma: Currently there are multiple Phase I/II clinical trials recruiting patients for combinational therapies, including Phase I/II trial of durvalumab, tremelimumab and radiation therapy in recurrent and metastatic HNSCC (NCT03522584), Phase II of nivolumab and ipilimumab for recurrent and metastatic HNSCC (NCT03620123), and Phase I of Interleukin-15 Superagonist (N-803) and ipilimumab in patients with advanced head and neck cancer (NCT04290546).